Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

November 17, 2026

BRISBANE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on November 14, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

The new non-executive employee received an option to purchase 300,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $3.92, which was the closing price of Annexon's common stock on November 13, 2026, the trading day immediately preceding the date of grant, and vest over 4 years, with 25% of the shares underlying the option vesting on the first anniversary of the employment start date and an additional 1/48th of the shares vesting monthly thereafter, subject to such employee's continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to harmful inflammation, tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon's mission is to deliver game-changing therapies to millions of patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com